AMG National Trust Bank Sells 187 Shares of Stryker Co. (NYSE:SYK)

AMG National Trust Bank lessened its position in shares of Stryker Co. (NYSE:SYKFree Report) by 1.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 17,136 shares of the medical technology company’s stock after selling 187 shares during the period. AMG National Trust Bank’s holdings in Stryker were worth $5,132,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Farmers & Merchants Trust Co of Chambersburg PA boosted its stake in Stryker by 203.3% during the fourth quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 91 shares of the medical technology company’s stock valued at $27,000 after buying an additional 61 shares during the period. Rogco LP bought a new position in shares of Stryker in the fourth quarter worth approximately $30,000. HBC Financial Services PLLC bought a new position in shares of Stryker in the fourth quarter worth approximately $37,000. Bourgeon Capital Management LLC bought a new stake in Stryker during the fourth quarter valued at approximately $37,000. Finally, Operose Advisors LLC grew its stake in Stryker by 308.6% in the 3rd quarter. Operose Advisors LLC now owns 143 shares of the medical technology company’s stock worth $39,000 after buying an additional 108 shares in the last quarter. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on SYK shares. BTIG Research raised their price objective on shares of Stryker from $366.00 to $369.00 and gave the company a “buy” rating in a research report on Wednesday, May 1st. Truist Financial raised their price objective on Stryker from $330.00 to $345.00 and gave the company a “hold” rating in a report on Wednesday, January 31st. Evercore ISI upped their target price on Stryker from $340.00 to $370.00 and gave the stock an “outperform” rating in a research note on Thursday, April 4th. Canaccord Genuity Group raised shares of Stryker from a “hold” rating to a “buy” rating and set a $360.00 price target on the stock in a research note on Wednesday, January 31st. Finally, TD Cowen upped their price objective on shares of Stryker from $365.00 to $400.00 and gave the company a “buy” rating in a research note on Thursday, April 11th. Four investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $365.94.

Read Our Latest Report on Stryker

Insider Transactions at Stryker

In other Stryker news, CAO William E. Berry, Jr. sold 7,690 shares of Stryker stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the completion of the transaction, the chief accounting officer now owns 3,675 shares in the company, valued at $1,317,414. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 5.90% of the company’s stock.

Stryker Stock Up 0.2 %

Stryker stock traded up $0.70 during trading hours on Friday, hitting $334.68. 940,474 shares of the stock traded hands, compared to its average volume of 1,622,308. Stryker Co. has a one year low of $249.98 and a one year high of $361.41. The firm’s 50-day moving average price is $342.20 and its two-hundred day moving average price is $322.20. The company has a current ratio of 1.71, a quick ratio of 0.99 and a debt-to-equity ratio of 0.56. The company has a market cap of $127.50 billion, a PE ratio of 38.21, a PEG ratio of 2.61 and a beta of 0.91.

Stryker (NYSE:SYKGet Free Report) last announced its earnings results on Tuesday, April 30th. The medical technology company reported $2.50 EPS for the quarter, beating analysts’ consensus estimates of $2.36 by $0.14. The firm had revenue of $5.24 billion for the quarter, compared to analysts’ expectations of $5.10 billion. Stryker had a net margin of 16.03% and a return on equity of 23.05%. The company’s quarterly revenue was up 9.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.14 EPS. On average, research analysts forecast that Stryker Co. will post 11.94 EPS for the current year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, July 31st. Stockholders of record on Friday, June 28th will be issued a dividend of $0.80 per share. The ex-dividend date is Friday, June 28th. This represents a $3.20 annualized dividend and a dividend yield of 0.96%. Stryker’s payout ratio is 36.53%.

Stryker Profile

(Free Report)

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

Further Reading

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.